Dataset Information

First in-vivo human imaging at 10.5T: Imaging the body at 447 MHz.

ABSTRACT:

Purpose

To investigate the feasibility of imaging the human torso and to evaluate the performance of several radiofrequency (RF) management strategies at 10.5T.

Methods

Healthy volunteers were imaged on a 10.5T whole-body scanner in multiple target anatomies, including the prostate, hip, kidney, liver, and heart. Phase-only shimming and spoke pulses were used to demonstrate their performance in managing the B1+ inhomogeneity present at 447 MHz. Imaging protocols included both qualitative and quantitative acquisitions to show the feasibility of imaging with different contrasts.

Results

High-quality images were acquired and demonstrated excellent overall contrast and signal-to-noise ratio. The experimental results matched well with predictions and suggested good translational capabilities of the RF management strategies previously developed at 7T. Phase-only shimming provided increased efficiency, but showed pronounced limitations in homogeneity, demonstrating the need for the increased degrees of freedom made possible through single- and multispoke RF pulse design.

Conclusion

The first in-vivo human imaging was successfully performed at 10.5T using previously developed RF management strategies. Further improvement in RF coils, transmit chain, and full integration of parallel transmit functionality are needed to fully realize the benefits of 10.5T.

SUBMITTER: He X

PROVIDER: S-EPMC7083701 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:Urokinase-type plasminogen activator receptor (uPAR) is overexpressed in human prostate cancer and uPAR has been found to be associated with metastatic disease and poor prognosis. AE105 is a small linear peptide with high binding affinity to uPAR. We synthesized an N-terminal NOTA-conjugated version (NOTA-AE105) for development of the first (18)F-labeled uPAR positron-emission-tomography PET ligand using the Al(18)F radiolabeling method. In this study, the potential of (18)F-AlF-NOTA-AE105 to specifically target uPAR-positive prostate tumors was investigated.NOTA-conjugated AE105 was synthesized and radiolabeled with (18)F-AlF according to a recently published optimized protocol. The labeled product was purified by reverse phase high performance liquid chromatography RP-HPLC. The tumor targeting properties were evaluated in mice with subcutaneously inoculated PC-3 xenografts using small animal PET and ex vivo biodistribution studies. uPAR-binding specificity was studied by coinjection of an excess of a uPAR antagonist peptide AE105 analogue (AE152).NOTA-AE105 was labeled with (18)F-AlF in high radiochemical purity (>92%) and yield (92.7%) and resulted in a specific activity of greater than 20GBq/?mol. A high and specific tumor uptake was found. At 1h post injection, the uptake of (18)F-AlF-NOTA-AE105 in PC-3 tumors was 4.22 ± 0.13%ID/g. uPAR-binding specificity was demonstrated by a reduced uptake of (18)F-AlF-NOTA-AE105 after coinjection of a blocking dose of uPAR antagonist at all three time points investigated. Good tumor-to-background ratio was observed with small animal PET and confirmed in the biodistribution analysis. Ex vivo uPAR expression analysis on extracted tumors confirmed human uPAR expression that correlated close with tumor uptake of (18)F-AlF-NOTA-AE105.The first (18)F-labeled uPAR PET ligand, (18)F-AlF-NOTA-AE105, has successfully been prepared and effectively visualized noninvasively uPAR positive prostate cancer. The favorable in vivo kinetics and easy production method facilitate its future clinical translation for identification of prostate cancer patients with an invasive phenotype and poor prognosis.